Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
暂无分享，去创建一个
M. J. van den Bent | M. Weller | T. Gorlia | J. Reijneveld | O. Chinot | M. Eoli | L. Dirven | V. Golfinopoulos | C. Coens | E. Franceschi | P. Sanghera | M. Spruyt | A. Walenkamp | N. Whenham | P. Clement | J. Frenel | J. Looman | J. Sepúlveda-Sánchez | F. D. De Vos | S. Nuyens | M. G. Kundu | Jan Peter de Geus